Chronic Kidney Disease

A new cohort study found that proteinuria and lower eGFR—particularly in combination—were prospectively associated with multiple domains of cognitive impairment in patients with chronic kidney disease (CKD).

Pharmacists are central to optimizing chronic kidney disease (CKD) diagnosis and monitoring long-term adherence to disease-modifying therapies.

Sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) were found to reduce the risk of chronic kidney disease (CKD) and key associated factors, like eGFR and albuminuria.

Cardiotoxic signals released from the kidneys may drive cardiovascular risk in patients with chronic kidney disease, opening the door to earlier detection and targeted treatment.

Patients with chronic kidney disease (CKD) send miRNA extracellular vesicles to the heart, contributing to the pathogenesis of heart failure.

Preeclampsia significantly raises the risk of chronic kidney disease (CKD) later in life, highlighting the need for targeted postpartum monitoring for affected women.

Recently released guidelines enhance chronic kidney disease management, emphasizing early detection and innovative treatments for better patient outcomes.

Study authors describe a framework to help patients with chronic kidney disease (CKD) change and adhere to diets.

New research highlights the efficacy and safety of HRS-1780, an investigational nonsteroidal MRA, in treating chronic kidney disease (CKD).

Although both sex groups showed cognitive decline, women with chronic kidney disease (CKD) had significantly better cognitive scores than men.

Research highlights the critical link between chronic kidney disease (CKD) and uncontrolled gout, emphasizing a need for enhanced awareness and treatment strategies.

Pharmacists leverage sodium-glucose cotransporter 2 (SGLT2) inhibitors to improve interconnected cardiovascular-kidney-metabolic (CKM) syndrome outcomes through holistic, patient-centered care.

The supplemental new drug application (sNDA) was assigned a PDUFA target action date of July 26, 2026.

Sibeprenlimab offers a groundbreaking treatment for immunoglobulin A nephropathy, targeting APRIL to reduce kidney damage and improve patient outcomes.

Data show the overall use of sodium-glucose cotransporter 2 (SGLT2) inhibitors among study participants with chronic kidney disease (CKD) was about 14.8%.

Particularly, younger women with chronic kidney disease (CKD) experienced the greatest survival disadvantage.

The research further emphasizes the need for more attention on both chronic kidney disease (CKD) and mental health conditions.

Pharmacists play a crucial role in holistic healthcare, enhancing patient care through education and collaboration with allied health professionals.

New findings reveal lorundrostat significantly lowers blood pressure and albuminuria in patients with chronic kidney disease, enhancing standard treatment efficacy.

Experts at AHA 2025 advocate for integrated care in T2D and CKD, emphasizing cardiovascular risk management to enhance patient outcomes.

Research highlights significant barriers to contraceptive use and reproductive health management for women with chronic kidney disease (CKD), urging improved nephrology care.

Although the incidence of vascular assess-associated infections (VAIs) was low, the incidence caused by noncuffed catheters (NCC) was high.

These negative effects were primarily presented when cells were stressed by inflammatory proteins in patients with chronic kidney disease (CKD) with APOL1 mutations.

In chronic kidney disease (CKD), SDMA showed a stronger connection to vascular health compared with ADMA.